Ipamorelin
Other ·Insufficient evidence ·Reviewed May 2026
Synthetic growth hormone secretagogue studied for pharmacology and postoperative ileus. FDA flags immunogenicity/impurity concerns and serious adverse events in an intravenous gastric-motility study.
- Unknown product purity, potency, and sterility risk outside regulated drug supply
- Injection-site reactions or infection risk with injectable products
- Immune reactions are possible with peptide impurities or aggregation
- Pregnancy or nursing
- History of cancer or active malignancy unless specifically cleared by an oncologist
The bottom line
Evidence rating insufficient. Most-documented uses: no approved wellness use, human efficacy evidence is insufficient for consumer guidance, reference-only safety profile. 3 sources indexed (1999–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Ghrelin receptor agonist that stimulates growth hormone release. This endocrine and GI-motility activity is not equivalent to proven safe wellness or body-composition use.3,1
Dosing & protocol.
Route-specific guidance is intentionally not provided for unapproved research peptides.
Full safety detail.
Side effects
- Unknown product purity, potency, and sterility risk outside regulated drug supply
- Injection-site reactions or infection risk with injectable products
- Immune reactions are possible with peptide impurities or aggregation
Contraindications
- Pregnancy or nursing
- History of cancer or active malignancy unless specifically cleared by an oncologist
- Use by competitive athletes subject to anti-doping rules
- Use without clinician supervision
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
1- 1Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsSource linkedPMIDBeck DE et al. · Int J Colorectal Dis · 2014
Clinical trial context was postoperative ileus, not consumer GH or recovery use.
Reference material
2- 2Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksSource linkedURLU.S. Food and Drug Administration · FDA · 2026
FDA flags immunogenicity/impurity concerns, unnatural amino-acid characterization complexity, serious adverse events including death in an IV gastric-motility study, and insufficient route-specific safety data.
- 3Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersSource linkedPMIDGobburu JV et al. · Pharm Res · 1999
Human volunteer PK/PD study confirms growth hormone releasing activity but does not establish wellness efficacy.
Deep dives & adjacent profiles.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Ipamorelin in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.